These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2004-001984-22 Essai randomisé de phase III comparant l’association traitement hormonal + docétaxel au traitement hormonal seul dans les cancers de la prostate métastatiques 2015-12-15 due-trials
Other 2004-002839-10 Phase II trial assessing the impact on instrumental and daily living autonomy of a chemotherapy regimen with bi-weekly docetaxel in the treatment of metastatic breast cancer in patients over the age o... not-yet-due
Reported results 2005-001072-13 A risk-adapted strategy of the use of dose-dense chemotherapy in patient with poor-prognosis dissemined non-seminomatous germ cell tumors. GETUG 13 / 0206 2021-05-03 due-trials
Ongoing 2005-005165-11 Etude randomisée multicentrique comparant l'efficacité d'une hormonothérapie courte par Zoladex® concomitante à une radiothérapie versus une radiothérapie exclusive dans le traitement de rattrapage de... not-yet-due
Ongoing 2006-003336-30 Essai de phase II multicentrique étudiant l’impact de la séquence thérapeutique radiochimiothérapie pré opératoire (50 Gy + capecitabine + oxaliplatine + cetuximab) suivie d’une chirurgie TME puis d’u... not-yet-due
Other 2006-003377-27 Etude Intergroupe (SFCE/GSF/GETO) OS2006 Zolédronate-Ostéosarcome Protocole de traitement des ostéosarcomes de l’enfant, de l’adolescent et de l’adulte comportant : - un essai randomisé - et des étud... not-yet-due
Ongoing 2006-006175-20 Essai de phase III évaluant la place de la ChimioHyperthermie IntraPéritonéale per opératoire (CHIP) après résection maximale d'une carcinose péritonéale d'origine colorectale associée à une chimioth... not-yet-due
Ongoing, reported early 2006-006409-10 Étude multicentrique de phase II randomisée, évaluant l’efficacité de l’anastrozole et du fulvestrant dans le traitement néo-adjuvant du cancer du sein opérable chez les femmes ménopausées et ayant po... not-yet-due
Ongoing 2006-006494-24 Randomized, open label, multicentric phase III trial evaluating the benefit of a sequential regimen associating FEC100 and Ixabepilone in adjuvant treatment of non metastatic, poor prognosis breast c... not-yet-due
Ongoing 2007-000687-24 Prévention du cancer du sein par le létrozole chez la femme ménopausée porteuse d'une mutation brca 1/2 not-yet-due
Ongoing 2007-002495-34 Etude randomisée multicentrique comparant une radiothérapie adjuvante immédidate associée à une hormonothérapie courte par analogue LH-RH (Décapeptyl LP®) vs une radiothérapie différée à la rechute b... not-yet-due
Reported results 2007-004098-24 A phase II, randomized, multi-center study, assessing value of adding RAD 001 to Trastuzumab as preoperative therapy of HER-2 positive primary breast cancer amenable to surgery 2015-03-31 due-trials
Ongoing 2007-007029-38 Essai de phase II multicentrique non randomisée étudiant l’impact de l’association radiochimiothérapie (65 Gy + cisplatine + 5FU) au cetuximab chez les patients présentant un cancer anal localement av... not-yet-due
Ongoing 2008-001084-10 A multicenter phase II clinical trial assessing the efficacy of the combination of lapatinib and capecitabine in patients with non pretreated brain metastasis from HER2 positive breast cancer. not-yet-due
Reported results 2008-004560-39 Essai de phase III multicentrique randomisé, comparant l’effet d’une chimiothérapie adjuvante de 6 mois par gemcitabine-oxaliplatine à 85mg/m² (GEMOX 85) à une surveillance, chez des patients opérés ... 2019-02-20 due-trials
Ongoing 2008-008167-99 Etude randomisée de phase III comparant l’Exemestane à un placebo chez des femmes ménopausées à risque élevé de cancer du sein. not-yet-due
Ongoing, reported early 2009-011882-10 Intensified methotrexate, vinblastine, doxorubicin and cisplatin (I-MVAC) with or without panitumumab as first-line treatment of advanced urothelial carcinoma in patients without H-Ras nor K-Ras mutat... not-yet-due
Completed, but no date, and reported results 2009-012797-12 Essai de phase II randomisé multicentrique évaluant l’efficacité d’une chimiothérapie seule ou combinée à l’AMG 102 ou au panitumumab en traitement de première ligne chez des patients atteints d’adéno... bad-data
Ongoing 2009-012813-22 Essai de phase II, randomisé multicentrique, évaluant le meilleur protocole de chimiothérapie associée à une thérapie ciblée choisie selon le statut KRAS dans les métastases hépatiques initialement no... not-yet-due
Reported results 2009-012942-22 Essai de phase II, randomisé multicentrique, évaluant l'efficacité d'une chimiothérapie standard à base de fluoropyrimidine associée au cétuximab ou au bévacizumab, chez des patients kras sauvage, att... 2019-02-20 due-trials
Ongoing, reported early 2009-015981-73 Phase II study evaluating the toxicity and activity of the combination lapatinib + capecitabine in elderly patients aged 70 and over with metastatic breast cancer over expressing HER2 not-yet-due
Reported results 2009-017092-24 Etude de phase II randomisée d’évaluation de la faisabilité d’une chimiothérapie par docetaxel prednisone sur un mode hebdomadaire ou toutes les 3 semaines dans une population de patients âgés (+75ans... 2013-06-20 due-trials
Other 2010-022037-29 Phase III randomised trial to evaluate the benefit of adjuvant hormonal treatment with leuprorelin acetate (Eligard® 45 mg) for 24 months after radical prostatectomy in patients with high risk of recu... not-yet-due
Other 2010-023035-42 Etude randomisée de phase III évaluant la Chimiothérapie Hyperthermique Intra Péritonéale dans le traitement du cancer de l’Ovaire en Récidive. not-yet-due
Reported results 2010-024046-29 Etude de phase II, randomisée, multicentrique, de l’Afatinib (BIBW2992) administré en pré-opératoire, chez des patients ayant un carcinome épidermoïde des voies aérodigestives supérieures non métastat... 2016-01-06 due-trials
Reported results 2011-001308-36 Etude de phase II multicentrique évaluant l’efficacité de la Gemcitabine en association avec le Pazopanib en traitement de seconde ligne des léiomyosarcomes utérins ou des tissus mous métastatiques ou... 2019-05-28 due-trials
Ongoing, reported early 2011-002026-52 Essai de phase III randomisé multicentrique comparant une chimiothérapie adjuvante de 6 mois par gemcitabine versus une association de 5-fluorouracile et acide folinique, irinotécan et oxaliplatine (m... not-yet-due
Ongoing 2011-004406-25 Etude randomisée de phase III comparant une radiochimiothérapie préopératoire à une chimiothérapie néoadjuvante Folfirinox suivie de radiochimiothérapie préopératoire pour les patients atteints de can... not-yet-due
Reported results 2011-004712-32 A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES. 2014-05-27 due-trials
Other 2011-004744-22 Adjuvant systemic treatment for oestrogen-receptor (ER)-positive HER2-negative breast carcinoma in women over 70 according to Genomic Grade (GG): chemotherapy + endocrine treatment versus endocrine tr... not-yet-due
Exempt 2011-004831-30 Safety and efficacy of radiotherapy combined with a 6-month LH-RH agonist and abiraterone hormone therapy treatment in biochemically-relapsing prostate cancer following surgery. not-yet-due
Ongoing 2012-000142-35 A Prospective randomized phase III study of Androgen deprivation therapy with or without docetaxel with or without local radiotherapy with or without local radiotherapy with or without ABIRATERONE ACE... not-yet-due
Reported results 2012-000167-25 A multicentric randomized phase II study evaluating dual targeting of the EGFR using the combination of cetuximab and afatinib versus cetuximab alone in patients with chemotherapy refractory wtKRAS me... 2018-03-30 due-trials
Ongoing 2012-000566-38 A randomized Phase III, factorial design, of cabazitaxel and pelvic radiotherapy in patients with localized prostate cancer and high-risk features of relapse not-yet-due
Ongoing 2012-001561-32 Etude de phase II randomisée multicentrique comparant l'efficacité d'une hormonothérapie courte concomitante à une radiothérapie versus une radiothérapie exclusive dans le traitement de rattrapage de ... not-yet-due
Completed, but no date, and reported results 2012-002525-29 A phase II trial evaluating the Activity of Abiraterone Acetate plus Prednisone in Patients with a Molecular Apocrine HER2-negative locally advanced or metastatic Breast Cancer. bad-data
Reported results 2012-002556-17 A randomized phase II trial of pertuzumab in combination with trastuzumab with or without chemotherapy, both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast ... 2020-05-31 due-trials
Other 2012-003187-44 Randomised, double-blind, multicentre phase III trial evaluating the safety and benefit of adding everolimus to adjuvant hormone therapy in women with high risk of relapse, ER+ and HER2- primary breas... not-yet-due
Ongoing, reported early 2012-004408-36 Etude de phase II évaluant l’efficacité du Pazopanib chez des patients ayant un carcinome des glandes salivaires en rechute et/ou métastatique. not-yet-due
Ongoing 2012-005139-99 Étude de phase II randomisée comparant un traitement d’entretien par cetuximab seul à une pause thérapeutique en cas de cancer colorectal métastatique avec gène KRAS sauvage répondeur ou contrôlés apr... not-yet-due
Ongoing 2013-000885-13 Secured access to crizotinib for patients with tumors harboring a genomic alteration on one of the biological targets of the drug not-yet-due
Ongoing, reported early 2013-001179-19 Prospective phase II study of Gemcitabine plus platinium salt in combination with bevacizumab (Avastin®) for metastatic collecting duct carcinoma. not-yet-due
Other 2013-001652-36 Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic breast cancer not-yet-due
Ongoing 2013-001653-27 Evaluation of the efficacy of high throughput genome analysis as a therapeutic decision tool for patients with metastatic non small cell lung cancer not-yet-due
Ongoing 2013-001800-13 Neoadjuvant phase II trial combining [3 FEC 100 followed by 3 docetaxel associated with trastuzumab plus pertuzumab] or [6 docetaxel, carboplatin associated with trastuzumab plus pertuzumab] according... not-yet-due
Other 2013-003910-42 A Randomized Phase II, placebo-controlled , multicenter study evaluating efficacy and safety of regorafenib in patients with metastatic bone sarcomas. not-yet-due
Other 2014-001225-33 Secured access to vemurafenib for patients with tumors harboring BRAF genomic alterations. not-yet-due
Reported results 2014-002560-33 Open-label, randomized, multicenter, international, parallel exploratory phase II study, comparing 3 FEC-3 Docetaxel chemotherapy to letrozole + palbociclib combination as neoadjuvant treatment of sta... 2020-04-02 due-trials
Completed, report not yet due Terminated 2014-003510-82 _ Essai de phase III, randomisé, comparant une chimiothérapie par Folfirinox à la gemcitabine dans le traitement du cancer pancréatique localement avancé 2024-04-08 not-yet-due
Other 2014-004678-41 Etude prospective de phase II d’évaluation d’une prise en charge multimodale des métastases ganglionnaires inguinales des carcinomes épidermoïdes du pénis par lymphadénectomie bilatérale et chimiothér... not-yet-due
Reported results 2015-000580-14 A single arm, open-label, phase II study to assess the efficacy of rucaparib in metastatic breast cancer patients with a BRCAness genomic signature. 2022-11-16 due-trials
Not reported 2015-004117-24 A Phase II Safety Trial of Nivolumab in Patients with Metastatic Renal Cell Carcinoma Who Have Progressed During or After Prior Systemic Anti-Angiogenic Regimen 2021-06-30 due-trials
Exempt, with results 2015-004340-19 Phase Ib/II trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) harboring a ... 2019-08-17 not-yet-due
Reported results 2016-000764-42 A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4... 2020-07-28 due-trials
Other 2016-001490-33 Phase II randomized study comparing FOLFIRINOX + Panitumumab versus mFOLFOX6 + Panitumumab in metastatic colorectal cancer patients selected by RAS and B-RAF status from circulating DNA analysis. not-yet-due
Other 2016-001491-29 A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high-risk stage III colon cancer in adjuvant setting not-yet-due
Ongoing 2016-001493-15 A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colore... not-yet-due
Ongoing 2016-001520-66 Efficacy and safety of fentanyl citrate in painful access induced during diagnostic or therapeutic examinations in cancer patients Efficacité et tolérance du citrate de fentanyl dans les accès doul... not-yet-due
Ongoing, reported early 2016-001794-32 A Phase II, Multicenter, Non Randomized, Open Label Study of Nivolumab In Recurrent and/or Metastatic Salivary Gland Carcinoma of the Head and Neck. not-yet-due
Completed, report not yet due 2016-002257-37 Secured access to nivolumab for adult patients with selected rare cancer types 2023-11-16 not-yet-due
Completed, report not yet due 2016-002260-14 Secured access to pembrolizumab for adult patients with selected rare cancer types. 2023-12-14 not-yet-due
Not reported 2016-002429-12 PERSONALIZED TREATMENT OF METASTATIC CASTRATE-RESISTANT PROSTATE CANCER PATIENTS ACCORDING TO CIRCULATING TUMOR CELLS KINETIC DURING CHEMOTHERAPY Traitement personnalisé des patients atteints de ca... 2021-08-26 due-trials
Other 2016-004360-18 Randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in estrog... not-yet-due
Ongoing 2017-000154-19 A phase II randomized trial comparing alpelisib and fulvestrant versus chemotherapy as maintenance therapy in patients with PIK3CA mutated advanced breast cancer not-yet-due
Other 2017-000155-21 An open label, randomized, phase III study, evaluating the efficacy of a Combination of Apalutamide with Radiotherapy and LHRH Agonist in high-risk postprostatectomy biochemically relapsed prostate ca... not-yet-due
Ongoing 2017-000424-10 A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN). not-yet-due
Other 2017-001165-24 A Multicentre, Randomised, Open-label, Phase 2 trial of mifamurtide combined with post-operative chemotherapy for newly diagnosed high risk osteosarcoma patients (metastatic osteosarcoma at diagnosis ... not-yet-due
Exempt 2017-001857-14 A phase I/II basket trial evaluating a combination of Metronomic Oral Vinorelbine plus anti-PD-L1/anti-CTLA4 ImmunothErapy in patients with advanced solid tumours. not-yet-due
Other 2017-002284-18 A randomized phase 2 study in patients with triple-negative, androgen receptor positive locally advanced (unresectable) or metastatic breast cancer treated with darolutamide or capecitabine Etude d... not-yet-due
Completed, but no date 2017-002320-25 Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: A phase II randomized study by the UNICANCER with cooperation of AFSOS. bad-data
Ongoing 2017-004512-19 An open label, randomized, phase III trial, evaluating efficacy of Atezolizumab in addition to one year BCG (Bacillus CaLmette-Guerin) bladder instillation in BCG-naive patients with high-risk non-mus... not-yet-due
Other 2017-005142-29 PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Immunothérapies et Irradiation concomitante sur des sites tumoraux variés dans les cancer... not-yet-due
Other 2018-000542-20 Randomized phase III study of oral cyclophosphamide vs doxorubicin in 65 years or older patients with advanced or metastatic soft tissue sarcoma: a UNICANCER/GERICO multicenter program not-yet-due
Ongoing 2018-000626-60 A multicenter, randomized, open label, phase II study evaluating the feasibility and tolerance of nivolumab neoadjuvant immunotherapy in high risk HPV driven Oropharynx Cancer. not-yet-due
Other 2018-000708-40 Association of Radiochemotherapy and Immunotherapy for the treatment of unresectable Oesophageal caNcer: a comparative randomized phase II trial. not-yet-due
Other 2018-001807-35 Phase II study of maintenance anti-PD-L1 treatment with atezolizumab after chemo-radiotherapy for muscle-infiltrating bladder cancer patients not eligible for radical cystectomy: Bladder Sparing not-yet-due
Reported results Terminated 2018-002374-46 A randomised phase II trial assessing REGorafenib combined with IRInotecan as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas. 2022-05-19 due-trials
Ongoing 2018-002886-21 A Phase III randomized study evaluating gemcitabine and paclitaxel versus gemcitabine alone after FOLFIRINOX failure or intolerance in Metastatic Pancreatic Ductal Adenocarcinoma. not-yet-due
Other 2018-003832-57 DOLAF- An international multicenter phase I/II trial of Durvalumab (MEDI4736) plus OLAparib plus Fulvestrant in metastatic or locally advanced ER-positive, HER2-negative breast cancer patients selecte... not-yet-due
Ongoing 2018-004868-57 Phase 2, Open label Study of DS-8201a, an Anti-HER2-AntIbody Drug Conjugate (ADC) for advanced BreaSt Cancer patients, with biomarkers analysis to characterize response/resistance to therapY not-yet-due
Other 2019-000260-14 Open-label, randomized, multicenter, phase III study, comparing standard chemotherapy to standard combination of endocrine therapy with Abemaciclib as initial Metastatic treatment among patients with ... not-yet-due
Other 2019-003839-33 Phase II basket trial evaluating the efficacy of a combination of pembrolizumab and vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma not-yet-due
Ongoing 2019-004052-11 A phase II trial assessing Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in a pre-operative setting for resectable and untreated head and neck squamous cell carcinoma not-yet-due
Listed as ongoing, but also has a completion date 2019-004196-39 A randomized, phase II study comparing the sequences of regorafenib and trifluridine/tipiracil, after failure of standard therapies in patients with metastatic colorectal cancer 2023-03-31 bad-data
Completed, but no date, and reported results 2019-004899-19 Adjuvant PalbOciclib + LetrOzole combination for hormone receptor positive / HER2-negative, Intermediate Risk breast cancer bad-data
Ongoing 2020-003108-15 A multicentric national phase II trial assessing TIslelizumab in monotherapy for patients with Hepatocellular Carcinoma Child-Pugh B and ALBI grade 1 or 2 liver function Score Essai de phase II, na... not-yet-due
Other 2020-003663-26 A double-blind randomised phase III trial evaluating the efficacy of ADT +/- darolutamide in de novo metastatic prostate cancer patients with vulnerable functional ability and not elected for docetaxe... not-yet-due
Other 2020-005735-79 Treatment with Tucatinib in addition to Pertuzumab and Trastuzumab in patients with HER2-positive metastatic breast cancer after local therapy of isolated brain progression TRAITEMENT PAR TUCATINIB... not-yet-due
Other 2021-000615-23 Randomized phase III trial of standard immunotherapy (IO) by checkpoint inhibitors, versus reduced dose intensity of IO in patients with metastatic cancer in response after 6 months of standard IO not-yet-due
Other 2021-002889-41 LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in women with HR+ HER2- breast cancer at very low risk of metastasis not-yet-due
Other 2021-005920-39 A phase II study of durvalumab (MEDI 4736) maintenance in frail limited disease small cell lung cancer patients after thoracic chemoradiotherapy (CRT) not-yet-due
Other 2021-006331-26 Phase 2, randomised trial testing the addition of upfront stereotactic radiosurgery to binimetinib, encorafenib plus pembrolizumab in comparison with binimetinib, encorafenib plus pembrolizumab alone ... not-yet-due
Other 2022-000273-81 Randomised phase II study evaluating trifluridine/tipiracil plus oxaliplatin versus FOLFOX in patients with gastric, oesophagus or gastroesophageal junction adenocarcinoma locally advanced, recurrent ... not-yet-due